To help you obtain continuing education credit as conveniently as possible, NJPhA provides an ongoing and expanding collection of coursework that can be completed from home. As indicated below, some programs are available to NJPhA members only.
If you have any questions about the home study programs, please contact the office.
Important credit information
Please note: If you completed the home study when the original issue of the journal was released, you can not obtain credit for completing it again online. Credit issued to an individual by the course UAN number once. Please carefully review your education record on CPE Monitor before enrolling in a home study program.
Click a course title for more information:
The Pathophysiology, Treatment, and Preventive Approaches in Herpes-zoster Infection
Nutrition Support in a Patient With Bechet's Disease
NJPhA Task Force: Opioid Abuse Treatment and Prevention Summary
New Drug Update: Delafloxacin (BaxdelaTM) for Acute Bacterial Skin & Skin Structure Infections
A Clinical Overview of Human Papillomavirus (HPV) Vaccines
A Systematic Review of Current eHealth Technologies That Foster Medication Adherence
Zika and the Pharmacist's Role
Resources to Optimize Medication Adherence
A Brief Review of Acetaminophen and N-Acetylcysteine and its Potential Concomitant Administration
The Pharmacist's Role in Wound Care with a Focus on Dressing Selection
Update on Lipid Management: American Association of Clinical Endocrinologists Hyperlipidemia Guidelines 2017
Dhara D. Shah, PharmD; Christine Lam, PharmD, BCPS, CDE, BCACP
**The authors have no financial or other relevant relationships to disclose.
(Members, free. Nonmembers, $15.)
Members must log in to obtain the members fee. Not a member? Join the Association
Audience
- Pharmacists
- Pharmacy Technicians
Credit
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-18-029-H04-P
- UAN: 0136-0000-18-029-H04-T
Release Date: August 15, 2018 Expiration Date: August 15, 2021
Activity Type: Knowledge-based
Goal
This paper aims to update pharmacists on the newly developed American Association of Clinical Endocrinologists (AACE) guidelines for management of hyperlipidemia to provide a practical guide for endocrinologists to reduce the risks and consequences of dyslipidemia
At the completion of this activity, pharmacists will be able to:
- Describe the change from the Four Statin Benefit Groups to ASCVD Risk Categories
- Apply the shift towards treat-to-target LDL-C levels based on recent evidence based medicine
- Relate the differences in the risk calculator utilized in the updated guidelines compared to previous guidelines to determine the 10-year ASCVD risk
- Explain the place in therapy for biomarkers and its association with coronary atherosclerosis
At the completion of this activity, technicians will be able to:
- Name the change from the Four Statin Benefit Groups to ASCVD Risk Categories
- Identify the shift towards treat-to-target LDL-C levels
- List the differences in the previous and updated risk calculators for a patient’s 10-year ASCVD risk
NJPhA Task Force: Opioid Abuse Treatment & Prevention Summary
Report Summary Compiled by Carmela Silvestri, PharmD, CCP from the work of the NJPhA Task Force on Opioid Addicition
**The authors have no financial or other relevant relationships to disclose.
(Members, free. Nonmembers, $15.)
Members must log in to obtain the members fee. Not a member? Join the Association
Audience
- Pharmacists
- Pharmacy Technicians
Credit
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-19-008-H01-P
- UAN: 0136-0000-19-008-H01-T
Release Date: February 27, 2019 Expiration Date: February 27, 2022
Activity Type: Knowledge-based
Goal
This activity explores the research findings of the NJPhA task force on Opioid Addiction Prevention and Treatment. The summary aims to provide pharmacists and technicians with an overview of the opioid epidemic in a variety of practice settings and provide tools for pharmacists and technicians in combating the opioid epidemic.
At the completion of this activity, pharmacists will be able to:
- Identify parts of the brain that are responsible for different aspects of opioid abuse
- Explain tools, practices, and policies to prevent opioid medication diversion and reallocation
- Describe abuse resistant drug formulations and list some of the formulations available
- Explain medication assisted treatment (MAT) for opioid use disorder (OUD)
At the completion of this activity, technicians will be able to:
- List elements of a fraudulent prescription
- Identify abuse resistant drug formulations
- Identify patients that may be victims of the opioid epidemic in a community pharmacy
- List methods of opioid disposal
The Pathophysiology, Treatment, and Preventive Approaches in Herpes-zoster Infection
Matthew Milone, PharmD/MBA Candidate Class of 2020; *Malgorzata Slugocki, PharmD, BCPS,
**The authors have no financial or other relevant relationships to disclose.
(Members, free. Nonmembers, $15.)
Members must log in to obtain the members fee. Not a member? Join the Association
Audience
- Pharmacists
Credit
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-19-017-H01-P
Release Date: May 20, 2019 Expiration Date: May 20, 2022
Activity Type: Knowledge-based
Goal
Herpes-zoster infection incidence is growing and affects millions of individuals worldwide, leading to
potentially debilitating complications. This review article is relevant to pharmacists in all areas of
practice, as it presents an overview of pathophysiology, treatment, and preventive approaches to herpes
zoster infection. Additionally, it provides a review on the newly approved Shingrix vaccine. It also sheds
light on the issue of continued backorder of the vaccine, and how to handle it, which remains an ongoing
problem. This concept is especially valuable to pharmacists practicing in the community setting.
At the completion of this activity, pharmacists will be able to:
- Understand the pathophysiology of herpes zoster infection
- Describe the typical clinical presentation of patients with herpes zoster
- Define available treatment approaches
- Describe the trials that led to Shingrix approval as well as current guidelines for administration
- Compare Zostavax and Shingrix vaccines
- Identify strategies on how to handle a Shingrix vaccine backorder
New Drug Update: Delafloxacin (BaxdelaTM) for Acute Bacterial Skin & Skin Structure Infections
Aamer Attaar, PharmD Candidate 2018; Marc Sturgill, PharmD
**The authors have no financial or other relevant relationships to disclose.
(Members, free. Nonmembers, $15.)
Members must log in to obtain the members fee. Not a member? Join the Association
Audience
- Pharmacists
- Pharmacy Technicians
Credit
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-18-021-H04-P
- UAN: 0136-0000-18-021-H04-T
Release Date: May 25, 2018 Expiration Date: May 25, 2021
Activity Type: Knowledge-based
Goal
This paper aims to update pharmacists on the use of delafloxacin in treating acute bacterial and skin structural infections.
At the completion of this activity, pharmacists will be able to:
- Recall specific characteristics of delafloxacin including mechanism of action, dosing, spectrum of coverage, adverse effects, and therapeutic use
- Analyze and interpret clinical trial data for delafloxacin as it relates to clinical relevance and pharmacokinetics
At the completion of this activity, technicians will be able to:
- Recall dosing, frequency, and duration of delafloxacin administration
- Recognize specific compounding and storage instructions for delafloxacin
Nutrition Support in a Patient With Bechet's Disease
Maria Leibfried, BS, PharmD, BCNSP; Andro Youssef, PharmD **The authors have no financial or other relevant relationships to disclose. (Members, free. Nonmembers, $15.) Members must login in to obtain the members fee. Not a member? Join the Association.- Pharmacists
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-19-026-H01-P
Objectives
At the completion of this activity, pharmacists will be able to:
- Identify complications of Behcet's disease
- List challenges in providing nutrition to a patient with Behcet's disease
- Describe why parenteral nutrition may be indicated in patients with Behcet's disease
A Clinical Overview of Human Papillomavirus (HPV) Vaccines
Oishi Rahman, PharmD; Brian Tong, PharmD; Kimberly Erin Ng, PharmD, BCPS*
*corresponding author
**The authors have no financial or other relevant relationships to disclose.
(Members, free. Nonmembers, $15.)
Members must login in to obtain the members fee. Not a member? Join the Association.
Audience
- Pharmacists
- Pharmacy Technicians
Credit
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-18-007-H06-P
- UAN: 0136-0000-18-007-H06-T
Release Date: February 20, 2018 Expiration Date: February 20, 2021
Activity Type: Knowledge-based
Goal
The purpose of this assessment is to inform healthcare professionals and allied health professionals of current trends in Human Papillomavirus (HPV) vaccines and their uses in patient HPV prevention.
Objectives
At the completion of this activity, pharmacists will be able to:
- Identify HPV Types and differentiate those which pose a risk factor for cancer.
- Describe currently available HPV vaccines
- Describe reccomendatiosn for HPV vaccines
- List adverse effects associatied with HPV vaccines
At the completion of this activity, pharmacist technicians will be able to:
- Define HPV
- List currently avialable HPV vaccines and HPV types covered by vaccines
- List adverse effects associated with HPV vaccines
A Systematic Review of Current eHealth Technologies That Foster Medication Adherence
Gino Sinigaglio, PharmD; Aakash Gandhi, PharmD; Rima Patel, MS; Grace Earl, PharmD*
*corresponding author **The authors have no financial or other relevant relationships to disclose. (Members, free. Nonmembers, $15.) Members must login in to obtain the members fee. Not a member? Join the Association.
- Pharmacists
- Pharmacy Technicians
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-17-034-H04-P
- UAN: 0136-0000-17-034-H04-T
Objectives
At the completion of this activity, pharmacists will be able to:
- Justify the use of specific eHealth technologies in improving medication adherence based on the evidence
- Identify the specific kind of adherence support provided by eHealth technology in improving medication adherence
- Distinguish the types of eHealth tools based on how the technology is used by the patient or pharmacist in improving medication adherence
At the completion of this activity, pharmacist technicians will be able to:
- Describe the extent of medication non-adherence affecting management of chronic diseases
- Identify the specific type of adherence support provided by eHealth technology in improving medication adherence
- Compare the specific types of eHealth technology tools based on the type of technology and type of adherence support
Current and Emerging Therapies of Recurrent Clostridium Difficile Infection: A Review of the Literature
Nicole L. Ryba, PharmD, BCPP, BCGP; Jesse B. Sullivan, PharmD, BCPS, BCCCP; Joseph Cavanaugh, PharmD, BCPS, BCCCP; Jessica Hill, PharmD, BCPS, BCACP **The authors have no financial or other relevant relationships to disclose. (Members, free. Nonmembers, $15.) Members must login in to obtain the members fee. Not a member? Join the Association.- Pharmacists
- Pharmacy Technicians
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-18-038-H01-P
- UAN: 0136-0000-18-038-H01-T
Objectives
At the completion of this activity, pharmacists will be able to:
- Define recurrent C. difficile infection (CDI)
- Describe guideline recommendations for primary CDI
- Describe guideline recommendations for recurrence of CDI
- Identify and Evaluate other emerging therapies for recurrent CDI
At the completion of this activity, pharmacist technicians will be able to:
- Identify first line treatment options for Clostridium difficile infection
- Describe appropriate dose of treatments options
- Describe appropriate formulation of treatment options
Resources to Optimize Medication Adherence
Sibyl M. Cherian, PharmD; Christine Lam, PharmD, BCPS **The author has no financial or other relevant relationships to disclose. (Members, free. Nonmembers, $15.) Members must log in to obtain the members fee. Not a member? Join the Association. Audience
- Pharmacists
- Pharmacy Technicians
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-17-019-H04-P
- UAN: 0136-0000-17-019-H04-T
Objectives
At the completion of this activity, pharmacists will be able to:
- Identify barriers to medication adherence
- Describe management systems and accountability system for coupons, vouchers, and patient assistant program
- Describe different strategies for improving patient education
At the completion of this activity, pharmacist technicians will be able to:
- List common medication adherence barriers
- Describe coupon options, vouchers, and patient assistance programs
- Explain patient education strategies
Zika and the Pharmacist
Asha Gupta, PharmD, RPh
**The author has no financial or other relevant relationships to disclose.
(Members, free. Nonmembers, $15.)
Members must log in to obtain the members fee. Not a member? Join the Association
Audience
- Pharmacists
- Pharmacy Technicians
Credit
- Contact hours: 1.0 (0.1 CEU)
- UAN: 0136-0000-16-035-H04-P
- UAN: 0136-0000-16-035-H04-T
Release Date: December 02, 2016 Expiration Date: December 02, 2019
Activity Type: Knowledge-based
Goal
This paper aims to highlight key points that healthcare professionals should know about the Zika virus, as it persists to threaten our communities and healthcare settings.
At the completion of this activity, pharmacists will be able to:
- Describe Zika viral transmission and prevalence
- Investigate the prevalence of the Zika virus globally, using information from reliable resources
- Explain to patients any available prevention methods
- Identify high-risk areas, populations at-risk, and patients who should be tested if there is possible Zika virus exposure
- Compile additional resources for personal knowledge and patient education
At the completion of this activity, technicians will be able to:
- Describe Zika viral transmission and prevalence
- Investigate the prevalence of the Zika virus globally, using information from reliable resources
- Identify additional resources for more information on Zika virus
A Brief Review of Acetaminophen and N-Acetylcysteine and its Potential Concomitant Administration
Timothy Nguyen, PharmD, BCPS, CCP, FASCP **The author has no financial or other relevant relationships to disclose. (Members, free. Nonmembers, $15.) Members must log in to obtain the members fee. Not a member? Join the Association Audience- Pharmacists
- Pharmacy Technicians
- Contact hours – 1.0 (0.1 CEU)
- UAN: 0136-0000-17-001-H04-P; 0136-0000-17-001-H04-T
After participating in this activity, the pharmacist shall be able to:
- Discuss the possible role of genetics in atopic dermatitis
- Recognize the role of probiocits in the primary prevention of atopic dermatitis
- State the pathophysiology of atopic dermatitis
After participating in this activity, the pharmacy technician shall be able to:
- Discuss the definition of a probiotic
- Discuss the possible roles of probiotics in the management of inflammatory disease
- State the role of atopic dermatitis in the allergy
The Pharmacist's Role In Wound Care witha Focus on Dressing Selection
Sean LaFlamme, PharmD, CWCA, CGP, BCPS **The author has no financial or business relationships to disclose in reference to this artricle (Members, free. Nonmembers, $15.) Members must log in to obtain the members fee. Not a member? Join the Association Audience- Pharmacists
- Contact hours: 0.5 (0.05CEU)
- UAN: 0136-0000-17-017-H04-P
At the completion of the activity, the pharmacists will be able to
- Determine the place in therapy for common wound care dressing products
- Identify medical conditions that effect wound healing
- Review different dressing classes
The New Jersey Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Proof of participation will be submitted to mycpemonitor.net within 60 days subject to documented attendance and completion of online evaluation materials.